Our history
It all started with beer brewing.
Two cousins, Yuyo Llamazares Vegh and Federico D’Alvia Vegh, learned to brew beer from their grandfather and did it as a hobby for friends and family.
Wanting to experiment with new types of beer, they realized they needed liquid yeast which wasn’t available at that time.
So, they decided to make their own.
The bigger problem.
Brewing beer is a bioprocess that uses yeast living cells. As they dived deeper into its production, they ran into a bigger challenge.
They realized that the traditional methods for bioprocessing hadn’t changed in a long time, and needed improvement in efficiency and scalability.
This was hindering innovation in fields that rely on bioprocesses, such as health, food, and energy.
Making biomanufacturing easy, scalable and repeatable.
Yuyo and Federico decided to shift their attention on solving this bottleneck in the biomanufacturing industry, and with the support of other companies and people, Stämm hasn’t stopped growing since.
Singularity University.
Thanks to its disruptive profile, Stämm’s concept model was selected by Singularity University -one of the most innovative academic institutions in the world- for its Global Innovation Program 2016.
Joining GridX’s portfolio.
Stämm became the first company in start-up accelerator GridX’s portfolio, with the goal of boosting Stämm’s growth exponentially.
IndieBio SF Batch 7.
IndieBio, the world’s largest biotech accelerator, invited founders Yuyo and Federico to participate in its biotech start-up development program.
Seed round.
Stämm raised a 2M Seed Round led by
Draper Associates.
The first facility.
Stämm inaugurated its first office and laboratories in downtown Buenos Aires.
The expansion continues.
Stämm opened a pilot-scale biofacility located in downtown Buenos Aires consisting of office space, laboratories and workshops.
Series A.
Stämm raised its Series A investment round, led by Varana Capital and opened its third location in Buenos Aires.
Third-party validation of our Bioprocessor.
Two prototypes of the Bioprocessor, our flagship product, were validated at the facilities of BioArk, the biotech startup accelerator in the canton of Valais, Switzerland.
This resulted in the highest antibody production values so far.
Stämm opened R&D facilities at BioArk.
In collaboration with the Greater Geneva Bern area (GGBa), Stämm opened R&D facilities at BioArk in Monthey, in the canton of Valais in Western Switzerland.